Astal Laboratories Limited has submitted a regulatory filing to BSE Limited, specifically addressed to The Deputy Manager (Department of Corporate Services). The document is a Statement of Deviation and Variation pursuant to Regulation 32(1), (2), and (3) of the SEBI (Listing Obligations and Disclosure Requirements), 2015, for the quarter ended September 30, 2026.
The filing confirms that the company raised funds amounting to ₹33.99 lakhs. The stated object for this fundraise was "To meet the long-term funding requirements of the Company for capital expenditure, working capital, general corporate purposes, etc. in order to support the future growth plan of the Company."
The company reported that the entire raised amount of ₹33.99 lakhs has been utilized. The disclosure explicitly states that there was no deviation or variation in the utilization of these funds. This means there was:
- (a) No deviation in the objects or purposes for which the funds were raised.
- (b) No deviation in the amount of funds utilized compared to what was originally disclosed.
- (c) No change in the terms of any contract referred to in the fund-raising document.
The modified allocation and the amount of deviation/variation for the quarter are both stated as "NIL."
This statement was reviewed by the company's Audit Committee in a meeting held on November 13, 2026. The letter was signed by Mahendra Kumar, Company Secretary & Compliance Officer (Membership No.: A71224).
Financial Impact
No financial impact from deviation or variation, as none occurred. The funds were utilized as originally intended.